Intestinal bacteria can reduce the risk of obesity and type 2 diabetes

The intestinal bacteria Akkermansia has been shown through recombinant mouse proteins to provide lasting benefits to overweight mice and to the intestine of diabetic animals. In the experiment, even after the pasteurization, the bacteria on the intestinal barrier strengthening effect still exist. These are the conclusion obtained by researchers at the Louvain Institute for Drug Research at the University of Louvain and researchers at the University of Wageningen and researchers at the University of Helsinki in Nature Medicine on November 28. Their results help to pave the way for the treatment of diabetes and obesity, but also for the treatment of cardiovascular disease and gastroenteritis.

In obese mice, the Patrice Cani group led by Willem M. De Vos and the Helsinki team led by Wageningen found that Akkermansia is able to prevent obesity and progress in type 2 diabetes in mice. The intestinal bacteria Akkermansia muciniphila found in mice has special effects on obesity and type 2 diabetes.

The Leuven group identified that Akkermansia's active form can reduce the effects of obesity and diabetes. Their team has confirmed that even after pasteurization - heating above 70 degrees Celsius, Akkermansia still prevents the disease from developing in mice. Pasteurization is attempted to inactivate the bacteria without destroying its properties. However, in its inactive state, bacteria continue to be effective against disease. "This is a surprising surprise," said William Devos. Even more shocking is that bacteria part become more active after the pasteurization. It not only reduced obesity and diabetes, but also prevents further development of these diseases.

The effectiveness of Akkermansia is greatly due to its inhibition of enteritis, such as enteritis or chronic irritable bowel syndrome. The applicability of intestinal bacteria to patients with obesity and diabetes is currently being tested in Brussels. The results are still expected, but the first clinical trial on the safety of the administration of intestinal bacteria in inactivated form was positive.

The team found that the unintended effect of pasteurized Akkermansia bacteria was due to the protein in the outer membrane of bacteria and was studied in the Wageningen team by Dr. Noora Ottman and Dr. Clara Belzer. This protein - Amuc_1100 * - maintains its function after being heated. Pasteurization inactivates the bacteria as a whole, not just the functional membrane proteins. The isolation of the protein makes it possible to develop drugs in concentrated form, which can also be used in the treatment of intestinal inflammation due to stress, alcoholism, liver disease and cancer.

Researchers have applied for multiple patents on their findings. In addition, separation companies are being developed to expand the production of Akkermansia bacteria and proteins. By the way, Flarebio offers good-quality recombinant proteins such as recombinant ITGB5 for your research.